The Peptide Industry Is Under the Microscope. And Federal Charges Are Coming.

As of today, Health Secretary RFK Jr. is publicly pushing the FDA to widen access to peptides, calling himself a big fan of the treatments and signaling imminent regulatory action. That sounds like good news for the industry. The federal enforcement machine has not slowed down one bit.

The peptide space sits in one of the most legally dangerous gray zones in American healthcare right now. Clinics are getting raided. Compounding pharmacies are receiving warning letters and losing their licenses. Online vendors are being shut down overnight. Telehealth companies are facing criminal indictments. None of that stops because RFK Jr. went on a podcast.

If you own, operate, prescribe for, or supply a peptide business in any form, you need to understand exactly where the legal exposure is.

Federal agents in a dark operations room reviewing enforcement documents and shipping records related to a peptide distribution network

Federal enforcement in the peptide space is accelerating. Raids, criminal indictments, and state-level injunctions are hitting the industry simultaneously.

The Legal Landscape: Why This Industry Is Such a Minefield

To understand why so many people in the peptide space are getting investigated, you need to understand the regulatory framework. Or more accurately, the absence of one.

The FDA divides drugs into two categories: approved and unapproved. Most peptides discussed in the wellness and biohacking world, BPC-157, TB-500, CJC-1295, ipamorelin, and others, have never gone through clinical trials. They have no approved label. They are not legal to compound and prescribe through ordinary pharmacy channels.

In 2023, the FDA moved more than a dozen of these peptides into Category 2 of the 503A Bulks List, the list of substances considered to have potential safety concerns. Once something lands on that list, licensed compounding pharmacies are prohibited from making it for human use. Full stop.

That created an industry problem. Clinics and practitioners who had been using these compounds for years suddenly had nowhere to legally source them. Two markets developed, and both carry serious criminal risk.

Close-up of FDA warning letters and enforcement documents spread on a desk

The FDA issued more than 50 warning letters to peptide vendors and compounders in 2024-2025. Many are escalating to criminal referrals.

⚖️ Key Legal Point

The gray market: products labeled "research use only," sold with disclaimers they are not for human consumption, then injected by patients anyway. The black market: illegal products manufactured in China, sold online with no quality controls, no testing, and no regulatory oversight. Both are actively targeted by the FDA, the DOJ, the DEA, and more than 40 state attorneys general.

What the Enforcement Looks Like Right Now

This is not theoretical.

In June 2025, the FDA raided the warehouse of Amino Asylum, one of the larger research peptide companies in the country. The site went offline and operations ceased immediately.

In early March 2026, Peptide Sciences, one of the most well-known research peptide vendors in the United States, voluntarily shut down and pulled its entire product catalog offline. At least seven other research peptide companies closed during 2025 alone. The "research use only" business model is collapsing under federal pressure.

The DOJ has already prosecuted companies criminally in this space. Tailor Made Compounding LLC was prosecuted by the DOJ for distributing unapproved peptides including BPC-157 and was forced to forfeit $1.79 million. That case established that the federal government is willing to bring criminal charges, not just civil penalties, against peptide businesses.

FDA Warning Letters and State-Level Enforcement

In late 2024 and throughout 2025, the FDA issued more than 50 warning letters to compounders, online sellers, and clinics marketing peptides for human use, even when those products carried "research use only" disclaimers. The FDA's position is clear: if the product is being sold for human injection, the label on the bottle does not matter.

More than 40 state attorneys general signed a joint letter demanding that the FDA and the Department of Homeland Security take coordinated action to stop the flow of illegal peptide products into the United States. Ohio has been one of the most aggressive states, suspending licenses and issuing settlement agreements against clinics and distributors found with BPC-157, AOD-9604, and ipamorelin on their shelves.

Alabama has already obtained a temporary restraining order against GLP-1 distributors at the state level. Other states are watching and following.

Federal raids in the peptide space are coordinated across the DOJ, FDA, DEA, and state attorneys general simultaneously.

Federal agents executing a search warrant at a medical clinic representing DOJ and FDA coordinated enforcement actions against peptide businesses

The Criminal Exposure: What Charges Look Like in This Space

If you are under investigation or have been contacted by federal agents, these are the charges being used:

Distribution of Unapproved Drugs (FDCA): Selling, dispensing, or distributing a drug not approved by the FDA is a federal crime. The "research use only" label provides no protection if the government can show the product was intended for human use.

Misbranding: If a product's label is false or misleading about its intended use, it is misbranded under federal law. Calling something a research chemical while selling it alongside syringes and dosing guides has already been the basis for multiple enforcement actions.

Healthcare Fraud (18 U.S.C. § 1347): If peptide services are being billed to Medicare, Medicaid, or private insurers, healthcare fraud charges can be layered on top of the drug distribution charges. Common in telehealth and medspa operations.

Anti-Kickback Violations: Patient referral arrangements, influencer marketing with embedded sales links, and clinic-to-pharmacy arrangements can all trigger Anti-Kickback Statute violations if anything of value is exchanged for patient referrals.

Wire Fraud (18 U.S.C. § 1343): Any misrepresentation made online, by email, or over the phone in connection with selling or promoting these products can support wire fraud charges, which carry up to 20 years per count.

Drug Importation Violations: Importing peptides from China or other foreign manufacturers without going through FDA-approved channels violates federal drug importation laws. Chinese peptide imports to the United States doubled to $328 million in 2025. Federal investigators know exactly where this product is coming from.

Money Laundering (18 U.S.C. § 1956): When proceeds from illegal drug distribution flow through business accounts, money laundering charges often follow. These carry up to 20 years per count and can ensnare accountants, investors, and business partners who were not directly involved in the drug side of the operation.

The RFK Jr. Factor: Why Hope Is Not a Legal Strategy

RFK Jr. has made it clear he wants wider access to peptides. He has called out the FDA for what he describes as aggressive suppression of these treatments. He has signaled that the FDA will allow about 14 peptides to be more accessible for compounding pharmacies. Key industry insiders connected to the administration have said it is a matter of when, not if.

Here is the legal reality as of today.

No FDA rule has changed. No Federal Register notice has been published. No statute has been amended. RFK Jr.'s public comments are policy direction, not law. Until a formal regulatory action is published and takes effect, every business operating in this space is still subject to the same legal framework that has been generating raids, warning letters, and criminal indictments.

Operating in anticipation of a regulation that has not yet been issued is not a legal defense. It is a gamble with criminal consequences.

Federal grand jury subpoena and FDA warning letter documents spread on a dark desk representing the legal exposure facing peptide businesses

By the time a federal agent contacts you in this space, there is already a file with your name on it. The investigation started long before that phone call.

Who Is Most at Risk Right Now

Based on current enforcement trends, these operators carry the highest exposure:

Online vendors selling research-grade peptides where marketing, packaging, or accompanying materials suggest human use
Compounding pharmacies producing Category 2 peptides without a clear legal pathway under current FDA rules
Telehealth companies prescribing peptides and billing insurance or Medicare for those services
Medspas and wellness clinics administering peptide injections sourced from gray market or unregistered suppliers
Influencers and marketers with affiliate links or commission arrangements tied to peptide product sales
Investors and holding companies with ownership stakes in peptide businesses who had knowledge of compliance concerns

🛡️ Defense Strategy

The most effective defense in a peptide case begins before indictment. Pre-charge intervention, engaging with federal prosecutors, presenting mitigating information, and narrowing the government's theory of the case carries far more leverage than post-indictment positioning. Once the indictment is filed, the window for influencing charging decisions closes.

What To Do If You Are Under Investigation or Have Been Contacted by Federal Agents

Do not speak to federal agents without a lawyer present.

Federal investigators working these cases are experienced. They are not stopping by to warn you. By the time an agent shows up at your door or calls your phone, there is already a file with your name on it.

Contact AMC Defense Law immediately. You need a federal criminal defense attorney who understands how FDA, DOJ, and DEA investigations in the healthcare and wellness space work.

Do not destroy, delete, or alter any records. Electronic records, purchasing records, supplier records, patient files, and communications must all be preserved exactly as they are. Destruction creates obstruction charges that are often easier to prove than the underlying offense.

Do not contact suppliers, employees, partners, or anyone else connected to the investigation. Any communication after you know you are under investigation can be charged as witness tampering or obstruction.

Getting defense counsel involved before an indictment is filed creates options that disappear the moment charges are announced publicly.

❓What happens if I receive an FDA warning letter for peptides?

A warning letter is serious and should not be ignored. Many warning letters in this space escalate to criminal referrals if the company does not comply promptly and completely. You should have legal counsel involved in drafting your response. Responding on your own, even in good faith, can lock you into positions that limit your legal options later.

❓Does the 'research use only' label protect me from federal criminal charges?

No. The FDA and DOJ have made clear in multiple enforcement actions that the label does not matter if the product is being sold and used as a drug. Courts have consistently rejected this as a defense.

❓Can I be charged even though the peptide regulations are currently unclear?

Yes. Federal prosecutors have been charging people in this space amid the regulatory uncertainty. The existence of a gray area does not mean you are protected from prosecution.

❓What if I genuinely did not know the peptides I was using were on the prohibited list?

Knowledge is an element of many federal charges, and genuine ignorance can sometimes be raised as a defense. However, given the volume of warning letters, media coverage, and enforcement actions in this space, prosecutors will argue you should have known. This argument needs to be structured carefully through experienced legal counsel.

❓Does cooperating with the FDA or DOJ help?

It can. But cooperation must be structured through your attorney. Responding to investigators or regulators on your own, even in good faith, can lock you into positions that severely limit your legal options later.

Federal Defense for the Peptide Industry

The peptide industry is moving fast and federal enforcement is moving faster. AMC Defense Law represents physicians, clinic operators, compounding pharmacies, telehealth companies, and wellness entrepreneurs facing federal and state investigations nationwide. We understand how these investigations are built, where they are vulnerable, and how to fight them at every stage.

Aaron M. Cohen, federal criminal defense attorney at AMC Defense Law, representing clients facing FDA, DOJ, and DEA investigations in the peptide and wellness industry

AMC Defense Law represents physicians, clinic operators, compounding pharmacies, and wellness entrepreneurs facing federal investigations nationwide.

If you or your loved ones have been arrested or are under investigation related to peptide business operations, call Aaron M. Cohen, 24 hours a day to get help.

The information on this page is for general informational purposes only and does not constitute legal advice. Reading this page does not create an attorney-client relationship.